Dr. Lal Path Labs Ltd. (LALPATHLAB:NSE) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Dr. Lal Path Labs Ltd. stock forecast from 0 analysts, the average analyst target price for Dr. Lal Path Labs Ltd. is not available over the next 12 months. Dr. Lal Path Labs Ltd.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Dr. Lal Path Labs Ltd. is Neutral, which is based on 8 positive signals and 7 negative signals. At the last closing, Dr. Lal Path Labs Ltd.’s stock price was INR 2,328.85. Dr. Lal Path Labs Ltd.’s stock price has changed by +0.06% over the past week, +9.40% over the past month and +21.53% over the last year.
No recent analyst target price found for Dr. Lal Path Labs Ltd.
No recent average analyst rating found for Dr. Lal Path Labs Ltd.
Company Overview Dr. Lal Path Labs Ltd.
Dr. Lal PathLabs Limited engages in the operation of laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs. The company was founded in 1949 and is based in Gurugram, India. Read Less
Dr. Lal PathLabs Limited engages in the operation of laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electropho...Read More
Frequently Asked Questions About Dr. Lal Path Labs Ltd. (LALPATHLAB:NSE) Stock
Stock Target Advisor's fundamental analysis for Dr. Lal Path Labs Ltd.'s stock is Neutral.
LALPATHLAB:NSE stock's dividend yield is 1.06%.
Our analysis grades LALPATHLAB:NSE stock's dividend yield at B. This means that LALPATHLAB:NSE stock's dividend yield is above 83% of the stocks in the Diagnostics & Research sector in the NSE exchange.
Based on this LALPATHLAB:NSE may be a good dividend stock for its sector.
Unfortunately we do not have enough data on LALPATHLAB:NSE's stock to indicate what its average analyst target is.
LALPATHLAB:NSE stock's Price/Earning ratio is 57.17.
Our analysis grades LALPATHLAB:NSE stock's Price / Earning ratio at F. This means that LALPATHLAB:NSE stock's Price/Earning ratio is above 50% of the stocks in the Diagnostics & Research sector in the NSE exchange.
Based on this LALPATHLAB:NSE may be fairly valued for its sector
The last closing price of LALPATHLAB:NSE's stock was INR 2,328.85.
The most recent market capitalization for LALPATHLAB:NSE is INR 188.20B.
Unfortunately we do not have enough analyst data on LALPATHLAB:NSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Dr. Lal Path Labs Ltd.'s stock.
As per our most recent records Dr. Lal Path Labs Ltd. has 4,048 Employees.
Dr. Lal Path Labs Ltd.'s registered address is Tower B, SAS Tower, Gurugram, India, 122001.
You can get more information about it from Dr. Lal Path Labs Ltd.'s website at https://www.lalpathlabs.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LALPATHLAB:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
